MedTrace Logo

Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

NCT07053709 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-01-13

No results posted yet for this study

Summary

Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD.

The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.

Conditions

  • Hyperuricemia and MAFLD

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Assiut University · Assiut University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2026-11-01
Completion
2027-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053709 on ClinicalTrials.gov